This investment positions the company to advance its bold vision of transforming medication access, adherence, and affordability across the United States. Windham Capital Partners led the round, alongside Citi Impact Fund, Samsung Next, and BrightEdge, and the investment arms of some of the nation's top health systems: Providence Ventures, OSF Healthcare, Inception Health, Ballad Ventures, UH Ventures, and UnityPoint Health Ventures. TailorMed also benefited from the continued support of its early investors: Sanara Ventures, Triventures, Accelmed, Almeda Ventures, and Bridges. The debt facility was led by Poalim-tech, part of Israel's leading bank, Bank HaPoalim.

TailorMed is a comprehensive, end-to-end platform designed to eliminate barriers along the entire medication journey, from affordability to access and adherence. TailorMed is building a new category in healthcare, transforming how stakeholders-patients, providers, pharmacies, life sciences, and payers-work together to ensure that every patient, across all medical conditions, can receive the treatment they need without delay. TailorMed's enterprise solution manages the full lifecycle of patient support programs, reducing the cost of care and driving better outcomes. Thanks to its partnerships with life sciences, TailorMed creates unparalleled automation through direct integration with manufacturer assistance programs.